Subtype
Malignant Female Reproductive System Neoplasm
CI-CAN-00003157Explore in graph →
1,464 active trials11 approved drugs128 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003157Explore in graph →
Clinical trials
6,254 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (740)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00513786 | Evaluation of Carboplatin/Paclitaxel/Bevacizumab in the Treatment of Advanced Stage Endometrial Carcinoma | completed | Phase 2 | 38 | David O'MalleyOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT02684227 | Enzalutamide, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrioid Endometrial Cancer | completed | Phase 2 | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 19, 2025 | clinicaltrials |
| NCT02489903 | RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) | completed | Phase 2 | 139 | EpicentRx, Inc.INDUSTRY | 1 | Mar 17, 2025 | clinicaltrials |
| NCT03268382 | p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246 | completed | Phase 2 | 36 | Aprea TherapeuticsINDUSTRY | 3 | Mar 17, 2025 | clinicaltrials |
| NCT03206047 | Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 1 / Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Mar 13, 2025 | clinicaltrials |
| NCT04380805 | A Study of AK104, a PD-1/CTLA-4 Bispecific Antibody in Subjects With Recurrent/Metastatic Cervical Cancer | completed | Phase 2 | 30 | AkesoINDUSTRY | 3 | Feb 28, 2025 | clinicaltrials |
| NCT04870177 | Study of AK112 in the Treatment of Advanced Gynecological Tumors | completed | Phase 2 | 53 | AkesoINDUSTRY | 1 | Feb 28, 2025 | clinicaltrials |
| NCT02428192 | Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Feb 25, 2025 | clinicaltrials |
| NCT04517357 | A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients | completed | Phase 2 | 100 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 24, 2025 | clinicaltrials |
| NCT04357873 | Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different Locations(PEVOsq) | completed | Phase 2 | 112 | UNICANCEROTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT04951921 | Hyperpolarized 13C Pyruvate MRI for Early Immune Evaluation in Cervical Cancer Patients At Baseline and CCRT Therapy | completed | Phase 2 | 6 | Chang Gung Memorial HospitalOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT01652196 | Aflibercept and FOLFOX6 Treatment for Previously Untreated Stage IV Colorectal Cancer | completed | Phase 2 | 56 | John HaysOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT01814501 | Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab | completed | Phase 2 | 16 | John HaysOTHER | 1 | Feb 5, 2025 | clinicaltrials |
| NCT00753545 | Assessment of Efficacy of AZD2281 in Platinum Sensitive Relapsed Serous Ovarian Cancer | completed | Phase 2 | 265 | AstraZenecaINDUSTRY | 17 | Feb 3, 2025 | clinicaltrials |
| NCT03532139 | Pilot Study of Rosuvastatin and Enoxaparin Thromboprophylaxis Following Ovarian Cancer Surgery (O-STAT Study) | completed | Phase 2 | 24 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jan 23, 2025 | clinicaltrials |
| NCT04275713 | Altered Tumor Oxygenation by Metformin, a Potential Step in Overcoming Radiotherapy Resistance in LACC(METOXY-LACC) | completed | Phase 2 | 41 | Oslo University HospitalOTHER | 1 | Jan 20, 2025 | clinicaltrials |
| NCT03241745 | A Study of Nivolumab in Selected Uterine Cancer Patients | completed | Phase 2 | 35 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT04731467 | A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 79 | Famewave Ltd.INDUSTRY | 3 | Dec 27, 2024 | clinicaltrials |
| NCT03997968 | A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 169 | Cyteir Therapeutics, Inc.INDUSTRY | 1 | Dec 24, 2024 | clinicaltrials |
| NCT03946358 | Combination of UCPVax Vaccine and Atezolizumab for the Treatment of Human Papillomavirus Positive Cancers (VolATIL)(VolATIL) | completed | Phase 2 | 47 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT02035787 | Metformin With the Levonorgestrel-Releasing Intrauterine Device for the Treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients | completed | Phase 2 | 20 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Dec 18, 2024 | clinicaltrials |
| NCT00170573 | Caelyx Biweekly in Heavily Pretreated Patients With Relapsed Ovarian Cancer | completed | Phase 2 | 77 | North Eastern German Society of Gynaecological OncologyOTHER | 0 | Dec 16, 2024 | clinicaltrials |
| NCT06115408 | Evaluation of Using Dienogest and N-Acetyl Cysteine on the Volume of Uterine Leiomyoma | completed | Phase 2 / Phase 3 | 40 | Ain Shams UniversityOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT02312245 | Avatar-Directed Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | completed | Phase 2 | 13 | Mayo ClinicOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT03745950 | UTOLA: UTerin OLAparib(UTOLA) | completed | Phase 2 | 147 | ARCAGY/ GINECO GROUPOTHER | 1 | Dec 4, 2024 | clinicaltrials |
| NCT01554397 | Study With Intensity Modulated Radiation Therapy With Cisplatin to Treat Stage I-IVA Cervical Cancer | completed | Phase 2 / Phase 3 | 101 | University of California, San DiegoOTHER | 6 | Nov 29, 2024 | clinicaltrials |
| NCT00889382 | A Study Evaluating Intermittent and Continuous OSI-906 and Weekly Paclitaxel in Patients With Recurrent Epithelial Ovarian Cancer (and Other Solid Tumors) | completed | Phase 1 / Phase 2 | 152 | Astellas Pharma IncINDUSTRY | 10 | Nov 20, 2024 | clinicaltrials |
| NCT02953457 | Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation | completed | Phase 2 | 40 | Roswell Park Cancer InstituteOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT03225989 | Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer | completed | Phase 1 / Phase 2 | 47 | Lokon Pharma ABINDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT03761914 | Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers | completed | Phase 1 / Phase 2 | 26 | Sellas Life Sciences GroupINDUSTRY | 1 | Nov 19, 2024 | clinicaltrials |
| NCT00170625 | Therapy With Topotecan and Carboplatin by Patients With Relapsed Ovarian Cancer | completed | Phase 1 / Phase 2 | 28 | North Eastern German Society of Gynaecological OncologyOTHER | 0 | Nov 12, 2024 | clinicaltrials |
| NCT03318900 | T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer | completed | Phase 1 / Phase 2 | 5 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT05227651 | AK104 in Neoadjuvant Treatment of Cervical Cancer | completed | Phase 2 | 14 | AkesoINDUSTRY | 1 | Nov 1, 2024 | clinicaltrials |
| NCT02040142 | HIPEC for Peritoneal Carcinomatosis | completed | Phase 2 | 51 | Albert Einstein College of MedicineOTHER | 1 | Oct 24, 2024 | clinicaltrials |
| NCT03345485 | Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.(EDO-S101) | completed | Phase 1 / Phase 2 | 71 | Mundipharma Research LimitedINDUSTRY | 5 | Oct 21, 2024 | clinicaltrials |
| NCT03648489 | Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)(DICE) | completed | Phase 2 | 134 | Imperial College LondonOTHER | 2 | Sep 20, 2024 | clinicaltrials |
| NCT05700669 | Study to Assess Safety and Efficacy of AsiDNA in Combination with Olaparib in Participants with Recurrent Solid Tumors | completed | Phase 1 / Phase 2 | 3 | Valerio TherapeuticsINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT02431676 | Survivorship Promotion In Reducing IGF-1 Trial(SPIRIT) | completed | Phase 2 | 121 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT01696032 | SGI-110 in Combination With Carboplatin in Ovarian Cancer(SGI-110) | completed | Phase 2 | 120 | Astex Pharmaceuticals, Inc.INDUSTRY | 3 | Aug 27, 2024 | clinicaltrials |
| NCT03602586 | Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer | completed | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 2 | Jul 26, 2024 | clinicaltrials |
| NCT02923934 | A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers | completed | Phase 2 | 120 | Olivia Newton-John Cancer Research InstituteOTHER | 1 | Jul 24, 2024 | clinicaltrials |
| NCT04570839 | COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. | completed | Phase 1 / Phase 2 | 48 | Compugen LtdINDUSTRY | 1 | Jul 18, 2024 | clinicaltrials |
| NCT03759600 | Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer | completed | Phase 2 | 20 | TakedaINDUSTRY | 1 | Jul 16, 2024 | clinicaltrials |
| NCT03989336 | A Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer | completed | Phase 2 | 84 | Chinese PLA General HospitalOTHER | 1 | Jul 15, 2024 | clinicaltrials |
| NCT04799639 | Efficacy and Toxicity of Paclitaxel, Cisplatin Combined With Sindilimab in NACT for Locally Advanced Cervical Cancer | completed | Phase 2 | 47 | Sun Yat-sen UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT03759587 | Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer | completed | Phase 2 | 19 | TakedaINDUSTRY | 1 | Jun 7, 2024 | clinicaltrials |
| NCT00194714 | Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab | completed | Phase 1 / Phase 2 | 22 | University of WashingtonOTHER | 1 | Jun 6, 2024 | clinicaltrials |
| NCT04205630 | SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma | completed | Phase 2 | 64 | Byondis B.V.INDUSTRY | 7 | May 30, 2024 | clinicaltrials |
| NCT03126812 | Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer | completed | Phase 1 / Phase 2 | 33 | The Netherlands Cancer InstituteOTHER | 1 | May 29, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Mar 28, 2025source: clinicaltrials